Losing Weight on a GLP-1? The Muscle Question Nobody Warned You About

A new kind of patient

Over the past couple of years a category of patient has appeared in this practice that essentially did not exist before: someone who has lost a substantial amount of weight on a GLP-1 receptor agonist (semaglutide, tirzepatide, or a relative) is genuinely pleased with the number on the scale, and is nonetheless unhappy with how their body looks and feels. They are often puzzled by this, because everything they were told framed weight loss as the goal, and they achieved it. The explanation is usually body composition.

What the research says about lean mass

When you lose weight rapidly by any means, some of what you lose is lean tissue rather than fat. This is not unique to GLP-1 medications. It is true of aggressive calorie restriction generally, but the magnitude has drawn attention because these drugs produce large, fast losses. Analyses of the major trials have reported that a substantial proportion of total weight lost is lean mass, with figures commonly cited in the range of a quarter to around forty percent depending on the study, the population, and how body composition was measured. The precise number is genuinely contested. The direction is not.

Why losing muscle matters more than it sounds

Muscle is not a cosmetic tissue. It is where most glucose disposal happens, it is what keeps you functional and independent as you age, and it is a meaningful contributor to how much energy you use. Losing a significant amount of it while losing fat leaves you lighter but not necessarily healthier, and it can make weight regain more likely afterwards. For an older patient, or anyone who was not carrying much muscle to begin with, that trade is worth taking seriously rather than treating as an acceptable side effect of a successful outcome.

The "skinny but soft" complaint

The presentation is consistent enough to be recognisable. Weight is down substantially, clothes fit differently, and yet the abdomen looks slack rather than flat, arms feel soft, and there is a general sense of having deflated rather than reshaped. Some of that is fat that remains in stubborn areas. Some is skin that has not retracted. And a good deal of it is the muscle underneath being smaller than it was, so there is less structure holding everything up. That last component is the one a muscle-building treatment can actually address.

Where EMSculpt NEO fits, and where it does not

It is not a substitute for the medication and it is not a substitute for resistance training, which remains the single best defence against losing muscle during weight loss, alongside adequate protein intake. What it can do is build muscle in a specific area, around twenty-five percent increase in the treated region in the published research, which makes it useful for patients whose training options are limited, or who want to address a particular area that has not responded. Reducing a remaining subcutaneous fat layer at the same time is a reasonable secondary benefit. What it cannot do is tighten loose skin, which is frequently the dominant issue after very large weight loss and needs an honest conversation about surgical options.

Timing, and talking to your prescriber

If you are still actively losing, there is a case for waiting until your weight has stabilised, so that you are building on a settled foundation rather than chasing a moving target. If you have plateaued or finished, that is a sensible point to assess what is left. Either way, tell us you are on the medication and keep your prescribing clinician in the loop. We are not managing that side of your care and we should not be working around it in the dark. Bring the details to the consultation and we will give you a straight assessment of whether this addresses what is actually bothering you.